OncoMatch/Clinical Trials/NCT03294889
ONE-SHOT Trial - Ultra-hypofractionated Single-dose SBRT for Prostate Cancer
Is NCT03294889 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies non-drug interventions for prostate cancer.
The main objective of the phase I/II trial is to determine the safety and efficacy of a single fraction SBRT at a dose of 19 Gy in patients with localized prostate cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage CT1C, CT2A, CT2B, CT2C (UICC TNM 2009 / AJCC)
Excluded: Stage CT3A, CT3B
Grade: Gleason 3+3Gleason 3+4WHO 2016 Grade Groups 1, 2 (Gleason / WHO 2016)
Tumor clinical stage cT1c-2c, pN0 or cN0, M0, according to UICC TNM 2009; MRI staging must confirm AJCC stage T1, T2a, T2b or T2c; Gleason score at biopsy 3+3 or 3+4 (WHO 2016 Grade Groups 1, 2)
Performance status
WHO 0–1
Prior therapy
Cannot have received: androgen deprivation therapy
Androgen deprivation therapy or products known to affect PSA levels
Cannot have received: pelvic radiotherapy
Prior pelvic radiotherapy
Cannot have received: surgery for prostate cancer
Previous surgery for prostate cancer
Cannot have received: transurethral resection of the prostate (TURP)
Exception: TURP < 12 weeks before registration
Previous transurethral resection of the prostate (TURP) (< 12 weeks before registration)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify